

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: N. Clayton et al.

Serial No.: To be assigned

Filed: Concurrently herewith

For: USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT  
OF NEUROPATHIC PAIN AND COLON CANCER

Box PCT/EO/DO/US  
Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☐ Copies of the references are enclosed

☐ Copies of the references were submitted in parent application Serial No. \_\_\_\_\_ (37 CFR 1.98(d))

☒ A copy of the International Search Report which issued on International Application No. PCT/EP00/07669 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449. (37 CFR 1.98(d)), and applicants understand that copies have been supplied to the USPTO by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$200.00).

C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- ☒ Please charge required fees to Deposit Account No. 07-1392.
- ☐ A duplicate copy of this paper is attached.

Date: 5 Feb 02

Respectfully Submitted,



Lorie Ann Morgan  
Attorney of Record, Reg. No. 38,181

GlaxoSmithKline  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Phone: (919) 483-8222  
Fax: (919) 483-7988